Orion OYJ (OTCMKTS:ORINY) Cut to “Hold” at Zacks Research

Zacks Research downgraded shares of Orion OYJ (OTCMKTS:ORINY) from a strong-buy rating to a hold rating in a research note published on Monday morning,Zacks.com reports.

Orion OYJ Stock Performance

OTCMKTS ORINY opened at $38.95 on Monday. The firm has a market capitalization of $10.99 billion, a P/E ratio of 26.50 and a beta of 0.11. Orion OYJ has a 1-year low of $21.95 and a 1-year high of $41.60. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.86 and a quick ratio of 1.05. The business’s 50-day simple moving average is $39.40 and its 200-day simple moving average is $34.18.

Orion OYJ (OTCMKTS:ORINY) last released its quarterly earnings data on Friday, July 18th. The company reported $0.33 earnings per share for the quarter. The business had revenue of $472.57 million for the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. Equities analysts predict that Orion OYJ will post 1.18 EPS for the current year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.